AdipoLABs wins the K-First In class Grand Prize for 7 consecutive years
High-frequency hyperthermia cancer treatment device ‘REMISSION 1℃’, leading innovation in cancer treatment field
Conference held on April 28-29th ... Introducing ‘REMISSION 1℃’ treatment cases
▲ AdipoLABs CEO Han Sung-ho (right) is receiving the K-First In Class grand prize.【Health and Welfare News】 ‘REMISSION 1℃’, a high-frequency hyperthermia cancer treatment device from AdipoLABs, Inc., which is leading innovation in the field of cancer treatment, is recognized for its best performance and technology.
AdipoLABs Co., Ltd. (CEO Han Sung-ho) announced that ‘REMISSION 1℃’ won the K-First In class Grand Prize for the 7th consecutive year at the 9th 2023 Korea Industry Awards held at the Korea Press Center on the 17th.
K-First In Class refers to a product selected for the first time in the medical industry by being recognized as a product with excellent performance and technology. AdipoLABs' REMISSION 1℃ is the product that boasts the highest technology and performance in the Korean medical device market.
‘REMISSION 1℃’ can treat cancer with much less invasiveness and pain than traditional surgical methods, and because it generates deep heat using high frequency waves, the device can intensively treat cancer without affecting human tissue.
In particular, ‘REMISSION 1℃’ has received high satisfaction from medical staff due to its latest technology and outstanding performance, and has established itself as a leader in the Korean medical device market.
AdipoLABs said it will continue to strive to improve its technology and performance and further increase the satisfaction of medical staff and patients.
Meanwhile, an international medical sharing conference introducing clinical trials and treatment cases of ‘REMISSION 1℃’ will be held at the Maria Hall of Seoul St. Mary’s Hospital for two days from April 28th to 29th.
The International Cancer Treatment Hope Conference, sponsored by Adipo LABs and hosted by IVRA (International Virus Research Association) and the Korean Society of Thermal Medicine, will invite domestic and foreign medical staff to introduce clinical trials and treatment cases of ‘REMISSION 1℃’.
‘REMISSION 1℃’ is a medical device that provides effective cancer treatment using the latest technology and is already providing stable and effective treatment to many patients in Korea.
At this conference, cases of patients treated using ' REMISSION 1℃' and clinical trial results will be introduced to the domestic and international medical community and patients, and current medical technology trends and cutting-edge research results in the field of cancer treatment will be shared with various experts.
Particularly, this International Medical Sharing Conference is a conference that attracts attention in the global medical community. Various domestic and foreign experts and researchers gather to share the latest research results and technology trends and exchange up to date treatment cases in the field of cancer treatment.
AdipoLABs plans to widely publicize the latest research results and treatment cases of the high-frequency hyperthermia cancer treatment device REMISSION 1℃ to the medical community around the world through the IVRA International Medical Sharing Conference, and provide more hope for the treatment of cancer patients.
